DRG2 supports the growth of primary tumors and metastases of melanoma by enhancing VEGF‐A expression

Malignant metastatic melanoma (MM) is the most lethal of all skin cancers, but detailed mechanisms for regulation of melanoma metastasis are not fully understood. Here, we demonstrated that developmentally regulated GTP‐binding protein 2 (DRG2) is required for the growth of primary tumors and for metastasis. DRG2 expression was significantly increased in MM compared with primary melanoma (PM) and dysplastic nevi. A correlation between DRG2 expression and poor disease‐specific survival in melanoma patients was also identified. Furthermore, inhibition of DRG2 suppressed the binding of Hypoxia‐inducible factor 1α to the VEGF‐A promoter region, expression of vascular endothelial growth factor (VEGF)‐A, and formation of endothelial cell tubes. In experimental mice, DRG2 depletion inhibited the growth of PM and lung metastases and increased survival. These results identify DRG2 as a critical regulator of VEGF‐A expression and of growth of PMs and lung metastases.

[1]  B. Lee,et al.  DRG2 knockdown induces Golgi fragmentation via GSK3β phosphorylation and microtubule stabilization. , 2019, Biochimica et biophysica acta. Molecular cell research.

[2]  Eun Hye Yoon,et al.  Developmentally regulated GTP-binding protein 2 depletion leads to mitochondrial dysfunction through downregulation of dynamin-related protein 1. , 2017, Biochemical and biophysical research communications.

[3]  Jeong Woo Park,et al.  DRG2 Regulates G2/M Progression via the Cyclin B1-Cdk1 Complex , 2016, Molecules and cells.

[4]  J. Espinosa,et al.  The TIP60 Complex Is a Conserved Coactivator of HIF1A. , 2016, Cell reports.

[5]  B. Lee,et al.  Developmentally regulated GTP-binding protein 2 coordinates Rab5 activity and transferrin recycling , 2016, Molecular biology of the cell.

[6]  B. Lee,et al.  Developmentally regulated GTP-binding protein 2 ameliorates EAE by suppressing the development of TH17 cells. , 2014, Clinical immunology.

[7]  G. Semenza,et al.  Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression , 2012, Proceedings of the National Academy of Sciences.

[8]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[9]  Chris T. Harvey,et al.  HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia* , 2011, The Journal of Biological Chemistry.

[10]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[11]  J. Folkman.  Opinion: Angiogenesis: an organizing principle for drug discovery? , 2007, Nature Reviews Drug Discovery.

[12]  L. Chin,et al.  Malignant melanoma: genetics and therapeutics in the genomic era. , 2006, Genes & development.

[13]  A. Chanmugam,et al.  Cutaneous malignant melanoma. , 2006, Mayo Clinic proceedings.

[14]  J. Cleveland,et al.  Two transactivation mechanisms cooperate for the bulk of HIF‐1‐responsive gene expression , 2005, The EMBO journal.

[15]  S. Ryter,et al.  FLIP Protects against Hypoxia/Reoxygenation-Induced Endothelial Cell Apoptosis by Inhibiting Bax Activation , 2005, Molecular and Cellular Biology.

[16]  J. Pouysségur,et al.  Transcriptional regulation of the Vascular Endothelial Growth Factor gene--a concert of activating factors. , 2005, Cardiovascular research.

[17]  H. Kato,et al.  Histone Deacetylase 7 Associates with Hypoxia-inducible Factor 1α and Increases Transcriptional Activity* , 2004, Journal of Biological Chemistry.

[18]  Hyo Jeong Kim,et al.  Overexpression of DRG2 increases G2/M phase cells and decreases sensitivity to nocodazole-induced apoptosis. , 2004, Journal of biochemistry.

[19]  Kyu-Won Kim,et al.  Hypoxia-inducible factor (HIF-1)α: its protein stability and biological functions , 2004, Experimental & Molecular Medicine.

[20]  Hyo Jeong Kim,et al.  Overexpression of DRG2 suppresses the growth of Jurkat T cells but does not induce apoptosis. , 2004, Archives of biochemistry and biophysics.

[21]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[22]  Christopher J. Schofield,et al.  Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL , 2002, Nature.

[23]  G. Semenza,et al.  HIF-1 and tumor progression: pathophysiology and therapeutics. , 2002, Trends in molecular medicine.

[24]  L. Ellis,et al.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.

[25]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[26]  N. Ferrara.  Role of vascular endothelial growth factor in regulation of physiological angiogenesis. , 2001, American journal of physiology. Cell physiology.

[27]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[28]  Christopher J. Robinson,et al.  The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.

[29]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[30]  S. Ugurel,et al.  Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Carmeliet.  Developmental biology: One cell, two fates , 2000, Nature.

[32]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[33]  B. Trueb,et al.  DRG represents a family of two closely related GTP-binding proteins. , 2000, Biochimica et biophysica acta.

[34]  B. Fingleton,et al.  Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  B. Smoller,et al.  Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[36]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[37]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  L. Poellinger,et al.  Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of theCBP/p300 coactivator by the hypoxia‐induciblefactor‐1α , 1998, The EMBO journal.

[39]  Y. Yoneda,et al.  A Nuclear Localization Signal of Human Aryl Hydrocarbon Receptor Nuclear Translocator/Hypoxia-inducible Factor 1β Is a Novel Bipartite Type Recognized by the Two Components of Nuclear Pore-targeting Complex* , 1997, The Journal of Biological Chemistry.

[40]  D. Livingston,et al.  Activation of Hypoxia-inducible Transcription Factor Depends Primarily upon Redox-sensitive Stabilization of Its α Subunit* , 1996, The Journal of Biological Chemistry.

[41]  S. Bhattacharya,et al.  An essential role for p300/CBP in the cellular response to hypoxia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[43]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[44]  B. Trueb,et al.  A novel GTP-binding protein which is selectively repressed in SV40 transformed fibroblasts. , 1994, The Journal of biological chemistry.

[45]  R. Halaban,et al.  Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. , 1993, Biochemical and biophysical research communications.

[46]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[47]  R. Kerbel,et al.  The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor , 2004, Angiogenesis.

[48]  L. Wolpert.  Developmental Biology , 1968, Nature.